Skip to main content

Advertisement

SpringerLink
Log in

New developments in anticoagulation for atrial fibrillation

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this indication. However, despite its efficacy, warfarin management is tedious and is useful only in a subsegment of the population who needs anticoagulation and has no contraindications. Many agents are poised to replace warfarin as an effective anticoagulant for stroke prevention in AF. The direct thrombin inhibitor dabigatran is furthest along in clinical development, followed by the factor Xa inhibitors rivaroxaban and apixaban. All these agents seem effective, and none appears mechanistically superior over another. Dabigatran’s advantage is that it was tested in two dosages in a phase 3 evaluation based on earlier phase 2 studies in patients with AF, whereas dosage data for the other agents were extrapolated from phase 2 programs for venous thromboembolism prevention. The vitamin K antagonist ATI-5923 offers clinical benefits similar to warfarin’s, but with no or fewer drug-drug interactions, potentially greater time in therapeutic range, and probably less need for dose adjustment and laboratory monitoring. It challenges the newer mechanistic agents in efficacy and raises the bar for comparison in future head-to-head trials. Further analysis and clinical trial testing are still needed to determine whether one or all of these agents are effective anticoagulants for stroke prevention in patients with AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Miyasaka Y, Barnes ME, Gersh BJ, et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114: 119–125.

    Article  PubMed  Google Scholar 

  2. Kannel WB, Abbott RD, Savage DD, et al.: Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982, 306: 1018–1022.

    PubMed  CAS  Google Scholar 

  3. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146: 857–867.

    PubMed  Google Scholar 

  4. Bungard TJ, Ghali WA, Teo KK, et al.: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000, 160: 41–46.

    Article  PubMed  CAS  Google Scholar 

  5. Connolly S, Pogue J, Hart R, et al.; ACTIVE Writing Group of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367: 1903–1912.

    Article  PubMed  CAS  Google Scholar 

  6. Albers GW, Diener HC, Frison L, et al.; SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293: 690–698.

    Article  PubMed  Google Scholar 

  7. Executive Steering Committee of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362: 1691–1698.

    Article  Google Scholar 

  8. Mant J, Hobbs FD, Fletcher K, et al.; BAFTA investigators; Midland Research Practices Network (MidReC): Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370: 493–503.

    Article  PubMed  CAS  Google Scholar 

  9. ARYx Therapeutics: Pharmacokinetic profile and study evaluation of ATI-5923. Available at www.aryx.com/wt/page/ati5923. Accessed June 2008. Pharmacologic and developmental data on ATI-5923.

  10. Carlquist JF, Horne BD, Muhlestein JB, et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006, 22: 191–197.

    Article  PubMed  CAS  Google Scholar 

  11. Bates SM, Weitz JI: The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000, 12(Suppl F): 27F–32F.

    PubMed  Google Scholar 

  12. Weitz JI, Leslie B, Hudoba M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998, 97: 544–552.

    PubMed  CAS  Google Scholar 

  13. Kaul S, Diamond GA, Weintraub WS: Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005, 46: 1986–1995.

    Article  PubMed  Google Scholar 

  14. Wallentin L, Ezekowitz M, Simmers TA, et al.: PETRO-investigators: Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin. Eur Heart J 2005, 26(Suppl): 482.

    Google Scholar 

  15. Mungall D: BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002, 3: 905–907.

    PubMed  CAS  Google Scholar 

  16. Ezekowitz MD, Reilly PA, Nehmiz G, et al.: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100: 1419–1426.

    Article  PubMed  CAS  Google Scholar 

  17. The Petro-ex Investigators: Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation [abstract 5]. Cerebrovasc Dis 2006, 21(Suppl 4): 2.

    Google Scholar 

  18. Bauer KA: New anticoagulants: anti IIa vs anti Xa—is one better? J Thromb Thrombolysis 2006, 21: 67–72.

    Article  PubMed  CAS  Google Scholar 

  19. Perzborn E, Strassburger J, Wilmen A, et al.: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3: 514–521.

    Article  PubMed  CAS  Google Scholar 

  20. Mueck W, Becka M, Kubitza D, et al.: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther 2007, 45: 335–344.

    PubMed  CAS  Google Scholar 

  21. Kubitza D, Becka M, Wensing G, et al.: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61: 873–880.

    Article  PubMed  CAS  Google Scholar 

  22. Kubitza D, Becka M, Mueck W, Zuehlsdorf M: The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor [abstract]. Blood 2006, 108: 905.

    Google Scholar 

  23. Kubitza D, Becka M, Zuehlsdorf M, Mueck W: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007, 47: 218–226.

    Article  PubMed  CAS  Google Scholar 

  24. Kubitza D, Becka M, Zuehlsdorf M, Mueck W: Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46: 549–558.

    Article  PubMed  CAS  Google Scholar 

  25. Pinto DJ, Orwat MJ, Koch S, et al.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007, 50: 5339–5356.

    Article  PubMed  CAS  Google Scholar 

  26. He K, He B, Grace JE, et al.: Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood 2006, 108: 910.

    Google Scholar 

  27. Lassen MR, Davidson BL, Gallus A, et al.: The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5: 2368–2375.

    Article  PubMed  CAS  Google Scholar 

  28. Koopman MM, Büller HR: Short-and long-acting synthetic pentasaccharides. J Intern Med 2003, 254: 335–342.

    Article  PubMed  CAS  Google Scholar 

  29. Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillation [press release]. Paris, France: Sanofi-Aventis; 2007. Available at http://en.sanofi-aventis.com/Images/070711_idraparinux_en_tcm24-18621.pdf. Accessed June 2008.

  30. Agnelli G, Haas S, Ginsberg JS, et al.: A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007, 5: 746–753.

    Article  PubMed  CAS  Google Scholar 

  31. Agnelli G, Haas SK, Krueger KA, et al.: A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY-517717) for the prevention of venous thromboembolism following TKR or THR [abstract]. Blood 2005, 106: 278.

    Google Scholar 

  32. Turpie AG, Gent M, Bauer K, et al.: Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT) [abstract]. J Thromb Haemost 2007, 5(Suppl 2): P-T–652.

    Google Scholar 

  33. Eriksson BI, Turpie AG, Lassen MR, et al.; ONYX study group: A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007, 5: 1660–1665.

    Article  PubMed  CAS  Google Scholar 

  34. Zafar MU, Vorchheimer DA, Gaztanaga J, et al.: Anti-thrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007, 98: 883–888.

    PubMed  CAS  Google Scholar 

  35. Neels JG, van Den Berg BM, Mertens K, et al.: Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000, 96: 3459–3465.

    PubMed  CAS  Google Scholar 

  36. Lawson JH, Mann KG: Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991, 266: 11317–11327.

    PubMed  CAS  Google Scholar 

  37. Ahmad SS, Rawala-Sheikh R, Walsh PN: Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989, 264: 20012–20016.

    PubMed  CAS  Google Scholar 

  38. Chow FS, Benincosa LJ, Sheth SB, et al.: Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002, 71: 235–245.

    Article  PubMed  CAS  Google Scholar 

  39. Dyke CK, Steinhubl SR, Kleiman NS, et al.: First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006, 114: 2490–2497.

    Article  PubMed  CAS  Google Scholar 

  40. Rothlein R, Shen JM, Naser N, et al.: TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonging bleeding times [abstract]. Blood 2005, 106: 1886.

    Google Scholar 

  41. Eriksson BI, Dahl OE, Lassen MR, et al.; for the Fixit Study Group: Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008, 6: 457–463.

    Article  PubMed  CAS  Google Scholar 

  42. Ragni M, Cirillo P, Pascucci I, et al.: Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996, 93: 1913–1918.

    PubMed  CAS  Google Scholar 

  43. Himber J, Kirchhofer D, Riederer M, et al.: Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997, 78: 1142–1149.

    PubMed  CAS  Google Scholar 

  44. Pawashe A, Golino P, Ambrosio G, et al.: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994, 74: 56–63.

    PubMed  CAS  Google Scholar 

  45. Szalony JA, Suleymanov OD, Salyers AK, et al.: Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res 2003, 112: 167–174.

    Article  PubMed  CAS  Google Scholar 

  46. Lee A, Agnelli G, Buller H, et al.: Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001, 104: 74–78.

    Article  PubMed  CAS  Google Scholar 

  47. Giugliano RP, Wiviott SD, Stone PH, et al.; for ANTHEM-TIMI-32 Investigators: Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007, 49: 2398–2407.

    Article  PubMed  CAS  Google Scholar 

  48. Shirk RA, Vlasuk GP: Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007, 27: 1895–1900.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA, 19096, USA

    Michael D. Ezekowitz

Authors
  1. M. Haris U. Usman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence A. Notaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harsh Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael D. Ezekowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael D. Ezekowitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Usman, M.H.U., Notaro, L.A., Patel, H. et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardio Med 10, 388–397 (2008). https://doi.org/10.1007/s11936-008-0030-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-008-0030-0

Keywords

Search

Navigation